Literature DB >> 6657739

An absolute must in clinico-pharmacological research: pharmaco-electroencephalography, its possibilities and limitations.

W M Herrmann, U Irrgang.   

Abstract

During drug development effects on blood cells, metabolism or function of heart and circulation are routinely examined. In case there is evidence of influence on such systems, examinations in clinical pharmacology are done. For the organ central nervous system the same rules should be followed, independently whether a substance is primarily a psychotropic drug or developed for other indications. Besides pharmacopsychological procedures pharmacoelectroencephalography is the most sensitive method to describe drug induced changes on brain function of humans. In event related research (e.g. evoked potentials) it is easier to form hypotheses for the mechanism of reaction after stimulation. About the validity of spontaneous cortical activity, like scalp recorded EEG we have little knowledge. However, a single signal of the spontaneous activity is analyzed into several components, each of which can be influenced differently by various drugs. Important areas of pharmacoelectroencephalography are: 1) Determination of CNS effects on a functional level; judgement whether a pharmacon has a potential for influencing CNS function in comparison to placebo. 2) Characterization of CNS-effects; determination of vigilance changes and classification of the profile in comparison to the EEG-effects of standards. 3) Determination of dose/efficacy and time/efficacy relations; description of kinetic data based on an effect-parameter, in contrast to blood levels; comparison of different galenic formulations; determination of onset and duration of effects; etc. 4) Determination of sleep-wake rhythms; measurement of influence on sleep/waking behaviour in the sleep laboratory or under vigilance controlled conditions during daytime.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6657739     DOI: 10.1055/s-2007-1019487

Source DB:  PubMed          Journal:  Pharmacopsychiatria        ISSN: 0720-4280


  6 in total

Review 1.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

2.  Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.

Authors:  J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

3.  Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats.

Authors:  T J Parker; O E Della Pasqua ; E Loizillon; C Chezaubernard; R Jochemsen; M Danhof
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  The effects of BRL 46470A, a novel 5-HT3 receptor antagonist, and lorazepam on psychometric performance and the EEG.

Authors:  C G Link; T J Leigh; J K Dennison
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

5.  EEG profile of intravenous zolpidem in healthy volunteers.

Authors:  A Patat; S Trocherie; J J Thebault; P Rosenzweig; C Dubruc; G Bianchetti; L A Court; P L Morselli
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

6.  Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters.

Authors:  H Wetzel; A Szegedi; C Hain; J Wiesner; S Schlegel; O Benkert
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.